Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Kristin Palmsten · HEALTHPARTNERS INSTITUTE · 2023 · $602,839 — The efficacy of coronavirus disease (COVID-19) vaccines available in the US is up to 95% against symptomatic COVID-19. However, pregnant and lactating individuals were excluded from initial clinical trials. COVID-19 vaccine trials are now underway in pregnant women in their second or third trimester…
WILLIAM R. SCHIEF · SCRIPPS RESEARCH INSTITUTE, THE · 2023 · $901,223 — Induction of broadly neutralizing antibodies (bnAbs) is a critical unmet goal of HIV vaccine development. BnAb 10E8 is of particular interest as a vaccine lead due to its (1) very high breadth, (2) low number of mutations required to develop broad neutralization, (3) low auto-reactivity, (4) expe…
Jordan Green · JOHNS HOPKINS UNIVERSITY · 2023 · $560,955 — PROJECT SUMMARY Cancer vaccines have significantly advanced cancer immunotherapy; and recent successes of mRNA vaccines have raised prospect of generating potent anti-tumor response by specifically delivering mRNAs encoding tumor-associated antigens to antigen presenting cells (APCs). However, APC a…
TERRY L. SHEPPARD · KEYSTONE SYMPOSIA · 2023 · $6,000 — ABSTRACT Support is requested for a Keystone Symposia conference entitled B Cells and Tertiary Lymphoid Structures: Emerging Targets in Cancer Therapeutics, organized by Drs. Tullia Bruno, Brad Nelson, Daniel Hollern and Marie-Caroline Dieu-Nosjean. The conference will be held in Whistler, British C…
Scott G Hansen · OREGON HEALTH & SCIENCE UNIVERSITY · 2023 · $795,947 — Project Summary With 36 million people currently living with HIV worldwide, developing a prophylactic HIV vaccine that protects against sexual transmission remains a top global health priority. A pre-clinical HIV vaccine approach based on strain 68-1 of rhesus cytomegalovirus expressing SIV antigens…
Lbachir BenMohamed · UNIVERSITY OF CALIFORNIA-IRVINE · 2023 · $409,999 — SUMMARY/ABSTRACT Herpes simplex type virus-1 (HSV-1) infects over 3.72 billion people worldwide, including 200 million individuals in the United States. Following primary infection of the cornea, HSV-1 establishes latency in sensory neurons of the trigeminal ganglia (TG). Reactivation of HSV-1 from …
Shinji Makino · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $309,206 — Coronaviruses (CoVs), which carry a large, single-stranded, positive-sense RNA genome, cause a variety of diseases in humans and domestic animals. Human CoVs (HCoVs) usually infect the respiratory tract and cause a range of symptoms varying from mild, such as the common cold, to more serious respira…
GILLIAN L BEAMER · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2023 · $526,177 — PROJECT SUMMARY/ABSTRACT Throughout modern history, tuberculosis (TB) has killed more people than any other infectious disease to date (estimated > 2 billion people over the past 350 years) and TB continues to kill 4,000 patients each day. In 2019 alone, the World Health Organization estimated that …
Darrell J Irvine · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $469,443 — Project Summary/Abstract The majority of licensed vaccines are thought to elicit protection mediated by humoral immunity. A key determinant of the specificity and affinity of the antibody response is the germinal center (GC) response elicited by immunization, wherein B cells enter GCs to undergo cyc…
Duane R. Wesemann · BRIGHAM AND WOMEN'S HOSPITAL · 2023 · $686,383 — Project Summary Antibodies specific for pathogenic threats can provide immediate protection from infectious disease but longevity of an antibody responses after vaccination or infection can be highly variable. Responses induced by some live vaccines can persist for a lifetime, whereas protein-based …
Gaurav Sahay · OREGON STATE UNIVERSITY · 2023 · $570,260 — PROJECT ABSTRACT RNA therapeutics and their corresponding nanomedicines are poised to rapidly change the landscape of healthcare. To address needs in various diseases, RNA-based technologies must function in vivo with biological interactions at various levels from whole body (systemic biodistributio…
Henry Charles Mwandumba · CORNELL UNIVERSITY · 2023 · $656,738 — Our recent advances in the use of fluorescent fitness reporter Mtb strains in the murine TB model has afforded us a unique appreciation of the role of macrophage lineages in both the control and promotion of Mtb growth. Moreover, the extension of these observations through the successful development…
Peter Shen · NORTHWESTERN UNIVERSITY AT CHICAGO · 2023 · $467,787 — PROJECT SUMMARY Poxviruses include family members that are categorized as Class A Priority Pathogens with significant future pandemic potential, while modified forms of other family members are widely used as vaccine vectors and oncolytic therapeutics. Beyond their more direct medical significance, …